Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
zXBN9eTrDSnWNrXX
